Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial - 21/03/24
, Colin Forsyth, PhD b, Irene Losada, MD a, Elena Trigo Esteban, PhD d, Magdalena García-Rodríguez, PhD e, Maria Luz Villegas, MD f, Israel Molina, PhD c, g, Clara Crespillo-Andújar, PhD c, d, h, Montserrat Gállego, PhD a, c, i, Cristina Ballart, PhD a, i, Juan Carlos Ramirez, PhD j, Tilman Aden, CMT k, Achim Hoerauf, MD k, l, Kenneth Pfarr, PhD k, l, Michel Vaillant, PhD m, Tayná Marques, MSc b, Jayme Fernandes, MD b, Bethania Blum, MSc b, Isabela Ribeiro, MD b, Sergio Sosa-Estani, PhD b, n, Fabiana Barreira, MD b, Joaquim Gascón, PhD a, con behalf of the
FEXI-12 Study Team†
Summary |
Background |
More than six million people worldwide, particularly in vulnerable communities in Latin America, are infected with Trypanosoma cruzi, the causative agent of Chagas disease. Only a small portion have access to diagnosis and treatment. Both drugs used to treat this chronic, neglected infection, benznidazole and nifurtimox, were developed more than 50 years ago, and adverse drug reactions during treatment pose a major barrier, causing 20% of patients to discontinue therapy. Fexinidazole proved efficacious in an earlier, interrupted clinical trial, but the doses evaluated were not well tolerated. The present study evaluated fexinidazole at lower doses and for shorter treatment durations.
Methods |
In this randomised, double-blind, phase 2 trial, we included adult patients (18–60 years old) with confirmed T cruzi infection by serology and PCR and without signs of organ involvement. We evaluated three regimens of fexinidazole—600 mg once daily for 10 days (6·0 g total dose), 1200 mg daily for 3 days (3·6 g), and 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6·6 g)—and compared them with a historical placebo control group (n=47). The primary endpoint was sustained negative results by PCR at end of treatment and on each visit up to four months of follow-up. This study is registered with ClinicalTrials.gov, NCT03587766, and EudraCT, 2016-004905-15.
Findings |
Between Oct 16, 2017, and Aug 7, 2018, we enrolled 45 patients (n=15 for each group), of whom 43 completed the study. Eight (19%) of 43 fexinidazole-treated patients reached the primary endpoint, compared with six (13%) of 46 in the historical control group. Mean parasite load decreased sharply following treatment but rebounded beginning 10 weeks after treatment. Five participants had seven grade 3 adverse events: carpal tunnel, sciatica, device infection, pneumonia, staphylococcal infection, and joint and device dislocation. Two participants discontinued treatment due to adverse events unrelated to fexinidazole.
Interpretation |
The fexinidazole regimens in this study had an acceptable safety profile but did not prove effective against T cruzi infection. Development of fexinidazole monotherapy for treating T cruzi infection has been stopped.
Funding |
The Drugs for Neglected Diseases initiative.
Le texte complet de cet article est disponible en PDF.Plan
Vol 24 - N° 4
P. 395-403 - avril 2024 Retour au numéro
Article précédent
- Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial
- Pau Bosch-Nicolau, Marisa L Fernández, Elena Sulleiro, Juan Carlos Villar, José A Perez-Molina, Rodrigo Correa-Oliveira, Sergio Sosa-Estani, Adrián Sánchez-Montalvá, Maria del Carmen Bangher, Otacilio C Moreira, Fernando Salvador, Ariela Mota Ferreira, Silvana Maria Eloi-Santos, Núria Serre-Delcor, Juan Carlos Ramírez, Aroa Silgado, Inés Oliveira, Oihane Martín, Maria Luisa Aznar, Antonio Luiz P Ribeiro, Paulo Emilio Clementino Almeida, Sandra Chamorro-Tojeiro, Juan Espinosa-Pereiro, Alfredo Mauricio Batista de Paula, Eliana Váquiro-Herrera, Carmen Tur, Israel Molina, MULTIBENZ Study Group
- Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial
- Maria Ubals, Patricia Nadal-Baron, Maider Arando, Ángel Rivero, Adrià Mendoza, Vicent Descalzo Jorro, Dan Ouchi, Clara Pérez-Mañá, Marlene Álvarez, Andrea Alemany, Yannick Hoyos-Mallecot, Ethan Nunley, Nicole A P Lieberman, Alexander L Greninger, Cristina Galván-Casas, Clara Suñer, Camila G-Beiras, Roger Paredes, Alicia Rodríguez-Gascón, Andrés Canut, Vicente García-Patos, Magí Farré, Michael Marks, Lorenzo Giacani, Martí Vall-Mayans, Oriol Mitjà
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?